Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

Metastatic Breast Cancer Clinical Trial

Official title:

Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01928680
• Other study ID #: LQ0001
• Secondary ID: CAMS-LQ0001
• Status: Active, not recruiting
• Phase: Phase 2
• First received: May 1, 2013
• Last updated: February 4, 2015
• Start date: November 2012
• Est. completion date: March 2016

Study information

• Verified date: February 2015
• Source: Chinese Academy of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

It is a phase II trial to explore the efficacy and safety of cisplatin plus capecitabine in anthracycline and taxane-pretreated metastatic triple negative breast cancer patients.

Description:

Cisplatin contained regimens have been demonstrated to be effective in metastatic triple negative breast cancer patients in some phase II clinical trials. Meanwhile, Capecitabine is also a highly effective choice for metastatic breast cancer with considerable duration of response. Combination of cisplatin and capecitabine have been proved effective in metastatic breast cancer in several phase II trials. This study is aimed to investigate the efficacy and safety of this combination in triple negative breast cancer patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 33
• Est. completion date: March 2016
• Est. primary completion date: October 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Written and signed informed consent prior to beginning specific protocol procedures.

• Pathologically confirmed Estrogen Receptor(ER), Progesterone Receptor(PR) and Human Epidermal growth factor Receptor HER-2) negative ("triple negative") breast cancer and documented metastatic or locally advanced disease.

Measurable disease - with at least 1 lesion measurable by radiological method

• KPS>=70

• 18 to 70 years old women

• Previously treated with an anthracycline and a taxane

• Hormone therapy for early-stage or metastatic breast cancer was permitted if hormonal receptor positive.

• Treatment with Herceptin for early-stage or metastatic breast cancer is permitted if HER2 positive

• Laboratory requirements:

• Hematology Absolute neutrophil count>=1,500 /µl; Platelets>=100,000 /µl; Hemoglobin>=10 g/dl

• Liver function Total bilirubin<=2 times ULN ASAT (SGOT) and ALAT (SGPT)<=2.5 times UNL without liver metastasis or <=5.0 times if liver metastasis Glucose<=200 mg/dL

• Renal function Serum creatinine<=140 mol/l

• Life expectancy of at least 12 weeks

• Patients must be accessible for treatment and follow-up.

• Patients should have recovered from the acute reversible effects of prior treatment. This generally means at least 3 weeks should have elapsed since prior chemotherapy, adjuvant or Neoadjuvant treatment. and at least 4 weeks since prior (radical) radiotherapy or major surgery

Exclusion Criteria:

• Women who are pregnant or breast feeding

• History of brain and/or leptomeningeal metastases

• Past or current history of malignant neoplasm other than breast carcinoma, except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years

• Pre-existing neuropathy grade 1 according to the NCIC-CTC 3.0

• Psychiatric disorders or other conditions which would prevent pt. compliance

• Other serious illness or medical condition:

• Congestive heart failure, or unstable angina pectoris, previous history of myocardial infarction within 6 month prior to study entry, uncontrolled hypertension as determined by the Investigator or high risk uncontrolled, arrhythmia.

• History of significant neurological or psychiatric disorders including psychotic disorders, dementia of seizures that would prohibit the understanding and giving of informed consent.

• Active uncontrolled infection.

• Unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of Corticosteroids.

• Inability to take and/or absorb oral medicine

• Prior treatment with capecitabine and/or cisplatin

• Concurrent treatment with other experimental drugs, or participation in another clinical trial with any investigational drug within 30 days prior to study entry

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Cisplatin/Capecitabine
Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity

Locations

Country	Name	City	State
China	Cancer Hospital, ChineseAMS	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate		6 months	No
Secondary	Progression Free Survival		2 years	Yes
Secondary	Overall Survival		3 years	Yes
Secondary	Number and Severity of Adverse Events of Patients Enrolled in This Trial	Number and severity of adverse events sufferred by patients who received capecitabine and cisplatin regimen.	1 year	Yes